ClinicalTrials.gg
TerminatedNCT03346538Updated Jul 16, 2026Results posted

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

A Phase 2 interventional study of Continuous infusion high-dose MCI-186 and Continuous infusion low-dose MCI-186 in Acute Ischemic Stroke, sponsored by Shionogi. Terminated at 45 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Enrollment
33rd of 35
17 · median 270
Started
2017
with 4 others
Phase 2
8 of 43
2 open now
Registered
21st of 43
by date
Lead sponsor
2 of 43
Shionogi

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 33rd largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2017, is one of 8 in phase 2, and was the 21st registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from whom written consent to study participation has been obtained, either from the patient personally or from the patient's legal guardian
  • Patients with age at consent between 20 and 85 years, inclusive
  • Patients for whom study treatment can be initiated within 24 hours after onset
  • Patients with confirmed new ischemic area only in the supratentorial region on MRI
  • Patients with neurological signs equivalent to between 4 and 22, inclusive, on the NIHSS

Exclusion criteria

Exclusion Criteria:

  • Patients with disability equivalent to an mRS score of 2 or more from before onset
  • Patients being treated with antibiotics for an infection at registration
  • Patients who have received or are planning to receive treatment for their primary disease with a prohibited concomitant medication (e.g., a thrombolytic drug) or with a prohibited concomitant therapy (e.g., intravascular therapy)
  • Patients for whom the (sub)investigator judges the efficacy endpoints (e.g., NIHSS, mRS, BI) that have been selected for this study can not be measured appropriately, such as patients who are not expected to achieve improvement of 4 or more on the NIHSS because of nerve symptoms that have been present since before the onset of cerebral infarction, Alzheimer's dementia patients, or Parkinson's disease patients
  • Patients with severe consciousness disturbances (Japan coma scale ≥ 100)
  • Patients with clear concurrent peripheral vascular disease or peripheral neuropathy for whom the (sub)investigator judges the neurological tests could not be performed properly
  • Patients with severe renal impairment (e.g., patients with \< 30)
  • Patients with severe hepatic impairment (e.g., , AST, or gamma-GTP > 2.5 X )
  • Patients with count \< 100,000/mm3
  • Patients diagnosed by MRI on admission with a disease other than stroke (e.g., intracranial bleeding, subarachnoid bleeding, arteriovenous malformations, Moyamoya disease, brain tumor) or with cerebral aneurysm with a maximum diameter > 7 mm
  • Patients with prior or current drug abuse or alcohol dependence
  • Patients with prior (or current) malignant tumor within 5 years before stroke onset
  • Patients with a past history of to edaravone drug products
  • Patients with concurrent heart disease severe enough to warrant admission and treatment (e.g., acute myocardial infarction, cardiac failure) and with problems with their overall condition judged by the (sub)investigator to be unsuitable for study participation
  • Patients for whom MRI tests cannot be performed
  • Male or female patients who do not consent to practice from the date of consent until the day after the administration of the last dose of study drug
  • Patients who are pregnant or nursing, or who could be pregnant
  • Patients who have received other drugs in the 12 weeks prior to consent acquisition
  • Patients with body weight ≥ 100 kg
  • Patients otherwise judged unsuitable for study participation by the (sub)investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Continuous infusion high-dose group (Group H)

    High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.

    Drug: Continuous infusion high-dose MCI-186 · Drug: Approved dosing regimen placebo

  • Experimental
    Continuous infusion low-dose group (Group L)

    Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.

    Drug: Continuous infusion low-dose MCI-186 · Drug: Approved dosing regimen placebo

  • Experimental
    Approved dosing regimen group (control group)

    A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.

    Drug: Continuous infusion placebo · Drug: Approved dosing regimen MCI-186

Interventions

  • DrugContinuous infusion high-dose MCI-186

    intravenous injection

  • DrugContinuous infusion low-dose MCI-186

    intravenous injection

  • DrugContinuous infusion placebo

    intravenous injection

  • DrugApproved dosing regimen MCI-186

    intravenous injection

  • DrugApproved dosing regimen placebo

    intravenous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With National Institutes of Health Stroke Scale (NIHSS) Score Improved.

    NIHSS is a scale to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40(severe stroke).

    Time frame: Baseline up to Day 7

Secondary outcomes

  1. Comparison of National Institutes of Health Stroke Scale (NIHSS)

    NIHSS is a scale used to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40 (severe stroke).

    Time frame: Day 14, at discharge(from Day15 to after 3 months) and after 3 months

  2. Number of Participants With Modified Rankin Scale (mRS) 0-1 at Each Evaluations

    mRS is a scale for measuring the degree of disability caused by a stroke. Possible scores range from Grade 0 (no symptoms) to Grade 6 (death). Number of Participants with Modified Rankin Scale (mRS) 0-1 are evaluated.

    Time frame: at discharge(from Day15 to after 3 months) and after 3 months

  3. Comparison of Barthel Index (BI)

    BI is a scale for measuring performance in Activities of Daily Living (ADL). Possible scores range from 0 (worst) to 100 (best).

    Time frame: at discharge(from Day15 to after 3 months) and after 3 months

  4. Comparison of Functional Independence Measure (FIM)

    FIM is a scale used to evaluate the functional status. Possible scores range from 18 (worst) to 126 (best).

    Time frame: at discharge(from Day15 to after 3 months) and after 3 months

07

Results

Posted Jan 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
Started746
Completed415
Not completed331
Withdrew: Physician decision010
Withdrew: Withdrawal by subject320
Withdrew: One subject of control group who discontinued prior to initiation of study drug administration.001

Outcome measures

PrimaryNumber of Participants With National Institutes of Health Stroke Scale (NIHSS) Score Improved.

NIHSS is a scale to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40(severe stroke).

Time frame:
Baseline up to Day 7
Reported as:
Count of participants · Participants
Number of Participants With National Institutes of Health Stroke Scale (NIHSS) Score Improved.
ParticipantsContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
Day 1000
Day 2201
Day 3201
Day 4201
Day 5201
Day 6311
Day 7311
SecondaryComparison of National Institutes of Health Stroke Scale (NIHSS)

NIHSS is a scale used to objectively quantify the neurologic impairment caused by a stroke. Possible scores range from 0 (no stroke symptoms) to 40 (severe stroke).

Time frame:
Day 14, at discharge(from Day15 to after 3 months) and after 3 months
Reported as:
Mean · units on a scale
Comparison of National Institutes of Health Stroke Scale (NIHSS)
units on a scaleContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
Day 143.7 ± 6.12.5 ± 2.12.8 ± 1.5
at discharge3.5 ± 5.12.0 ± 1.43.3 ± 1.5
after 3 months3.3 ± 3.20.0 ± NA1.8 ± 0.8
SecondaryNumber of Participants With Modified Rankin Scale (mRS) 0-1 at Each Evaluations

mRS is a scale for measuring the degree of disability caused by a stroke. Possible scores range from Grade 0 (no symptoms) to Grade 6 (death). Number of Participants with Modified Rankin Scale (mRS) 0-1 are evaluated.

Time frame:
at discharge(from Day15 to after 3 months) and after 3 months
Reported as:
Count of participants · Participants
Number of Participants With Modified Rankin Scale (mRS) 0-1 at Each Evaluations
ParticipantsContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
at discharge413
after 3 months213
SecondaryComparison of Barthel Index (BI)

BI is a scale for measuring performance in Activities of Daily Living (ADL). Possible scores range from 0 (worst) to 100 (best).

Time frame:
at discharge(from Day15 to after 3 months) and after 3 months
Reported as:
Mean · units on a scale
Comparison of Barthel Index (BI)
units on a scaleContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
at discharge80 ± 36.772.5 ± 38.983.3 ± 28.9
after 3 months90 ± 17.3100 ± NA100 ± 0
SecondaryComparison of Functional Independence Measure (FIM)

FIM is a scale used to evaluate the functional status. Possible scores range from 18 (worst) to 126 (best).

Time frame:
at discharge(from Day15 to after 3 months) and after 3 months
Reported as:
Mean · units on a scale
Comparison of Functional Independence Measure (FIM)
units on a scaleContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
at discharge102.2 ± 33.891.5 ± 41.7121.8 ± 4.1
after 3 months93.7 ± 54.3125.0 ± NA123.4 ± 2.5

Adverse events

Collected over Adverse events occurring in subjects up to 3 months after the start of investigational product treatment were investigated.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Continuous Infusion High-dose Group (Group H)0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Continuous Infusion Low-dose Group (Group L)0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Approved Dosing Regimen Group (Control Group)0/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/71/30/5
Hepatic massHepatobiliary disorders0/70/31/5
Transient ischaemic attackNervous system disorders1/70/30/5
Most frequent other events
Showing 10 of 25
Most frequent other events
EventContinuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)
ConstipationGastrointestinal disorders3/71/31/5
Urinary tract infectionInfections and infestations0/71/30/5
Chondrocalcinosis pyrophosphateMusculoskeletal and connective tissue disorders0/71/30/5
DeliriumPsychiatric disorders1/71/30/5
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/71/30/5
DermatitisSkin and subcutaneous tissue disorders0/71/30/5
Eczema asteatoticSkin and subcutaneous tissue disorders0/71/30/5
PsoriasisSkin and subcutaneous tissue disorders0/71/30/5
UrticariaSkin and subcutaneous tissue disorders0/71/30/5
HeadacheNervous system disorders2/70/31/5

Baseline characteristics

Among the randomised of 17 subjects, the baseline participants consisted of 15 subjects, excluding 1 who withdrew their consent after randomization and 1 who discontinued prior to initiation of study drug administration.

Age, Continuous
Age, Continuous(years)Continuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)Total
Mean76.3 ± 6.875.7 ± 7.464.4 ± 11.272.2 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Continuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)Total
Female62311
Male1124
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Continuous Infusion High-dose Group (Group H)Continuous Infusion Low-dose Group (Group L)Approved Dosing Regimen Group (Control Group)Total
Japanese73515
Non-Japanese0000
08

Study locations

45 sites
  • Investigational site 13
    Aichi, Japan
  • Investigational site 39
    Aomori, Japan
  • Investigational site 19
    Chiba, Japan
  • Investigational site 28
    Chiba, Japan
  • Investigational site 33
    Ehime, Japan
  • Investigational site 10
    Fukui, Japan
  • Investigational site 05
    Fukuoka, Japan
  • Investigational site 09
    Fukuoka, Japan
  • Investigational site 11
    Fukuoka, Japan
  • Investigational site 12
    Fukuoka, Japan
  • Investigational site 18
    Fukuoka, Japan
  • Investigational site 21
    Fukuoka, Japan
  • Investigational site 32
    Fukuoka, Japan
  • Investigational site 37
    Fukuoka, Japan
  • Investigational site 07
    Fukushima, Japan
  • Investigational site 08
    Fukushima, Japan
  • Investigational site 15
    Gifu, Japan
  • Investigational site 23
    Gifu, Japan
  • Investigational site 02
    Gunma, Japan
  • Investigational site 01
    Hokkaido, Japan
  • Investigational site 22
    Hokkaido, Japan
  • Investigational site 06
    Hyōgo, Japan
  • Investigational site 30
    Hyōgo, Japan
  • Investigational site 42
    Hyōgo, Japan
  • Investigational site 43
    Ishikawa, Japan
  • Investigational site 40
    Kanagawa, Japan
  • Investigational site 24
    Kochi, Japan
  • Investigational site 35
    Miyagi, Japan
  • Investigational site 16
    Nagano, Japan
  • Investigational site 20
    Nagano, Japan
  • Investigational site 27
    Numakunai, Japan
  • Investigational site 44
    Okayama, Japan
  • Investigational site 41
    Okinawa, Japan
  • Investigational site 03
    Osaka, Japan
  • Investigational site 25
    Osaka, Japan
  • Investigational site 38
    Saga, Japan
  • Investigational site 31
    Saitama, Japan
  • Investigational site 14
    Shimane, Japan
  • Investigational site 29
    Tochigi, Japan
  • Investigational site 36
    Tochigi, Japan
  • Investigational site 17
    Tokyo, Japan
  • Investigational site 45
    Tokyo, Japan
  • Investigational site 34
    Yamagata, Japan
  • Investigational site 04
    Yamaguchi, Japan
  • Investigational site 26
    Yamaguchi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in May 2018, 5 months.

Results were first posted in Jan 2025, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 17, 2017
StartActual
Nov 17, 2017
Primary completionActual
May 14, 2018
CompletionActual
May 14, 2018
Results first posted
Jan 9, 2025
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03346538
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 17, 2017
Primary completion
May 14, 2018
Completion
May 14, 2018
Results posted
Jan 9, 2025
Last update
Jul 16, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion